Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19749101 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL29433900 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL16648788 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL27530381 | 0.75 | FABP7 (0.43) | KMT2AHPGDCHRM2CHRM4CHRM5 | |
| Bicarbonate SCHEMBL29739771 | 0.74 | ALDH1A1 (0.50) | MEN1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL31629597 | 0.74 | TSHR (0.42) | MEN1KMT2ASIGMAR1TSHRALDH1A1 | |
| SCHEMBL19318895 | 0.74 | HPGD (0.49) | MEN1KMT2AHPGDTSHRALDH1A1 | |
| SCHEMBL25642129 | 0.74 | TSHR (0.45) | MEN1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL26704669 | 0.73 | TSHR (0.44) | RAB9ATSHRALDH1A1 | |
| SCHEMBL8466630 | 0.72 | ELANE (0.49) | KMT2AHPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 531/4885KMT2A 1917/4885HPGD 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.